SomaLogic raises up to $60.5 million from Visium Healthcare Partners to support strategic growth initiatives

SomaLogic raises up to $60.5 million from Visium Healthcare Partners to support strategic growth initiatives

3/1/2016

SomaLogic, Inc., and Visium Healthcare Partners, LP today announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium. The proceeds will be used to support SomaLogic’s continued growth, including its primary focus on the development of novel life science tools and clinical diagnostics based on the company’s proprietary proteomics technology. Specific terms of the agreement were not disclosed.

“We are very pleased to partner with Visium Healthcare Partners, who have created a customized financing structure that enables us to meet our capital needs and continue to execute our strategic growth initiatives,” said Byron Hewett, Chief Executive Officer of SomaLogic. “This investment underlines their recognition of our significant potential, and gives us the opportunity to leverage their deep healthcare sector expertise during the critical next stage of SomaLogic’s development.”

“SomaLogic’s proprietary SOMAmer and SOMAscan technologies provide researchers and clinicians with a level of proteomic information that promises to revolutionize how diseases are diagnosed and treated,” said Avi Amin, MD, Partner of Visium Healthcare Partners. “We believe that SomaLogic is an incredibly compelling emerging healthcare company and expect that this investment will help accelerate the realization of their ambitious vision and vast potential.”

SomaLogic’s technology platform gives researchers and clinicians critical tools for protein biomarker discovery, diagnostics development and pharmaceutical innovation. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types, accelerating the discovery of biomarkers across a wide range of diseases and conditions.

“We welcome Visium as a long-term financial partner supporting our rapidly expanding efforts to provide state-of-the-art, sensitive, accurate and highly multiplexed proteomics tools for both clinical and research needs,” said Larry Gold, PhD, Founder and Chairman of SomaLogic. “This infusion of growth capital provides us with the opportunity to more quickly realize our ultimate goal of delivering much-needed new diagnostics tests to the clinic.”


SomaLogic completes agreement with Bristol-Myers Squibb for expanded access to SOMAmer reagents

SomaLogic completes agreement with Bristol-Myers Squibb for expanded access to SOMAmer reagents

1/11/2016

SomaLogic, Inc., announced today that it signed an agreement with the Bristol-Myers Squibb Company (NYSE-BMY) to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay, as well as custom SOMAmer reagents developed through SomaLogic’s SOMAmer Discovery Service specifically for Bristol-Myers Squibb. Specific terms of the agreement were not disclosed.

“We’re excited that Bristol-Myers Squibb has selected our SOMAmer reagents as tools for their drug discovery and development research,” said Byron Hewett, Chief Executive Officer of SomaLogic. “We look forward to a long and productive relationship between their scientists and ours as we work with them to integrate our technology into their research.”

SOMAmer (Slow Off-rate Modified Aptamer) reagents are a new generation of protein-binding molecules that combine the best properties of antibodies and traditional aptamers. Each SOMAmer reagent consists of a unique, short single-stranded DNA sequence that incorporates several bases that have been modified to include “protein-like” side chains. These unique chemical properties confer on SOMAmer reagents both high affinity and specificity for their target proteins as well as high durability and reproducibility, making them attractive reagents for virtually every laboratory assay that currently relies on antibodies.

To date, SomaLogic has developed thousands of SOMAmer reagents to a broad array of different proteins critical to normal and disease biology, and it continues to expand its publicly available SOMAmer reagent library at regular intervals. SomaLogic currently offers individual research users access to several hundred of its individual SOMAmer reagents, as well as the discovery of “fit-for-purpose” custom SOMAmer reagents through its SOMAmer Discovery Service.


SomaLogic announces deployment of SOMAscan® assay to Beth Israel Deaconess Medical Center (BIDMC)

SomaLogic announces deployment of SOMAscan® assay to Beth Israel Deaconess Medical Center (BIDMC)

12/17/2015

SomaLogic announced today that the Beth Israel Deaconess Medical Center in Boston, MA, is the latest academic center to deploy the SOMAscan assay in support of the protein biomarker discovery and development efforts of its research community. The SOMAscan assay will be performed under the leadership of Towia Libermann, PhD, Director of the BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center and the Dana–Farber/Harvard Cancer Center (DF/HCC) Cancer Proteomics Core.

“We are delighted to partner with Beth Israel Deaconess Medical Center, a world-class medical research center and teaching hospital of Harvard Medical School, to expand the availability of the SOMAscan assay to BIDMC’s incredible scientists and to investigators at other academic centers in Boston,” said Byron Hewett, Chief Executive Officer of SomaLogic. “Under the strong leadership of Dr. Libermann, we believe that this expanded access will lead to many new breakthrough discoveries in biology and medicine.”

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates over 1,300 different SOMAmer reagents, can efficiently, accurately and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

BIDMC is the tenth named academic center to deploy the SOMAscan assay “in-house.” SomaLogic is continuing efforts to make its technology more easily available to researchers worldwide, and will announce additional new SOMAscan assay sites over the next several months.


SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

12/7/2015

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics*, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis (RA) in a cynomolgus monkey model of the disease. The SOMAmer molecule used in these studies, named SL1026, was initially selected for its ability to directly bind and block the signaling of the critical inflammatory protein interleukin-6 (IL-6), which is known to be involved in RA onset and progression.

“SL1026 represents a new class of drug candidates for the treatment of diseases where interleukin-6 plays a central role, including cancer and other inflammatory diseases in addition to RA,” said Nebojsa Janjic, Chief Science Officer at SomaLogic. “These initial studies reinforce and extend the large potential of SOMAmer molecules as therapeutic agents.”

The researchers tested SL1026 in a total of 24 cynomolgus monkeys. Pharmacokinetic studies of the molecule in 12 monkeys across a range of doses established the dosing regimen for determining its effects on rheumatoid arthritis onset and progression in the other 12 animals. The complete results are available in the Nucleic Acid Therapeutics manuscript, which is available to all readers under an “open access” license.

“Our collaboration with Otsuka researchers over the past several years has been incredibly productive and gratifying,” said Byron Hewett, Chief Executive Officer at SomaLogic. “Its world-class expertise in drug development has made it a terrific partner for exploring the promise of our rapidly growing SOMAmer reagent library for addressing critical unmet need for novel therapeutics. We believe that the RA work is just the first of what will be many successful studies.”

Although there is no cure for RA, there are several treatment options for trying to manage the disease. Notable among these is the biological agent Actemra® (tocilizumab, Genentech), an antibody based drug that binds the IL-6 receptor protein, thus preventing IL-6 signaling through its receptor. Because it is based on nucleic acids rather than amino acids, SL1026 offers certain advantages over antibody-based drugs such as tocilizumab, including the lack of an immune response to the drug itself (as demonstrated in the published manuscript), and a more consistent chemical rather than biological synthesis method.

SomaLogic scientists can select SOMAmer reagents that specifically bind virtually any protein of interest, including those that are known to be important drug targets across a wide range of diseases and conditions.

*Hirota M. et al. (2015). Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. Nucleic Acid Therapeutics DOI: 10.1089/nat.2015.0567.


SomaLogic announces College of American Pathologists (CAP) accreditation of its CLIA laboratory

SomaLogic announces College of American Pathologists (CAP) accreditation of its CLIA laboratory

12/1/2015

SomaLogic, Inc. announced today that its SomaLogic Clinical Laboratory (CLIA laboratory) has been registered with the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988, and has received accreditation by the College of American Pathologists (CAP).

“The CAP accreditation of our CLIA laboratory is an important milestone on our way to applying our unique proteomic technology to the transformation of research and clinical diagnostics,” said Byron Hewett, CEO of SomaLogic. “Through our CLIA laboratory, we will be able to provide a growing range of cutting-edge tests and assays across many different diseases for the academic and pharmaceutical research communities and, soon, for clinical providers and their patients.”
SomaLogic’s upcoming new SOMAmer reagent-based test offerings from its CLIA laboratory are based on novel protein biomarker combinations, or “signatures,” which have been discovered through the application of the company’s SOMAscan assay to a wide array of many different diseases and conditions.

SomaLogic’s CMS Registration Number is 06D2093281, and its CAP Accreditation Number is 7223571. SomaLogic is in full compliance with all provisions (including the Privacy and Security Rules) of the Health Insurance Portability and Accountability Act of 1996.


SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

11/12/2015

SomaLogic was recognized as “Company of the Year” by the Colorado BioScience Association (CBSA) at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing “a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.” Chairman and Founder Larry Gold and CEO Byron Hewett accepted the award on behalf of the company.

CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers.
For more information, please visit the CBSA website.